Exploratory biomarker analysis of phase 3 ASTRUM-004 study: serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer III期ASTRUM-004临床研究的探索性生物标志物分析:斯鲁利单抗联合化疗...
1. Zhou C. First-line camrelizumab(Camre)plus carboplatin(Carbo)and pemetrexed(Pem)for advanced non-squamous NSCLC:5-yr outcomes of CameL phase 3 study.2024 ELCC. 61P. 2. Zhou C, Chen G, Huang Y, et al. Camre...
[5]Jie Wang, et al. 2022 ESMO-IO.#132P. [6]Wang J, Lu S, Yu X, et al. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 May 1;7(5):709-717. do...
Musso E, Havel L, Bondarenko I, Losonczy G, Conev N, Mann H, Dalvi TB, Jiang H, Goldman JW. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small
Cancer Commun (Lond). 2022 Nov 6. Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3) https://pubmed.ncbi.nlm.nih.gov/36336841/...
术语“治疗(treatment)”、“治疗(treating)”或其任何变体包括减少、改善或消除(i)一种或多种特定症状,和/或(ii)特定障碍的一种或多种症状或影响。术语“预防(prevention)”、“预防(preventing)”或其任何变体包括降低、改善或消除发展(i)一种或多种特定症状和/或(ii)特定障碍的一种或多种症状或影响的风险。
[1]Zhou C, et al. Camrelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer: 4-yr update from the phase 3 CameL-sq trial. 2024 ELCC. 62P. [2]Zhou C, et al. Camrelizumab plus chemotherapy (Cam-chemo) as first-line (1L) therapy for...
cancer. It is also one of six studies where PD-1/L1 inhibitors are used as comparators. This initiative is a critical step in advancing cancer immunotherapy, establishing superior global treatment standards, and exploring the full clinical and commercial potential of ivonescimab within Akeso's ...
The FGFR1 amplification proved unreliable as the predictive biomarker for FGFR inhibitors (FGFRIs) in the treatment of Sq-NSCLC. It was suggested that other genomic aberrations within FGFR1 and other genes might affect response to FGFRIs. We aimed to comprehensively evaluate the set of genomic and...
Cancer Commun (Lond). 2022 Nov 6. Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3) https://pubmed.ncbi.nlm./36336841/...